Particle.news
Download on the App Store

Texas Sues Bristol-Myers Squibb and Sanofi Over Alleged Deception on Plavix’s Effectiveness

Texas alleges violations of state consumer and healthcare-fraud laws tied to undisclosed genetic limits on the drug's effectiveness.

Overview

  • The State of Texas filed suit on Nov. 20 naming Bristol-Myers Squibb and Sanofi-Aventis U.S. in the 71st District Court of Harrison County.
  • The complaint alleges the companies failed to disclose that Plavix can be ineffective for many patients, particularly Black, East Asian, and Pacific Islander individuals, due to genetic metabolism differences.
  • Texas cites the Deceptive Trade Practices Act and the Healthcare Program Fraud Prevention Act and claims billions in wasted taxpayer funds, including Texas Medicaid spending.
  • Attorney General Ken Paxton brought the case with private counsel from McKool Smith and The Lanier Law Firm, and public statements accuse the companies of putting profits over patient safety.
  • The filing is at an initial stage with no case number reported and no company responses noted in the coverage.